LEF1 and cancer: In summary, the novel four‐gene signature (CD8A, CD8B, TCF7, and LEF1) could serve as a predictive biomarker of the immune responses to ICB and clinical outcomes of patients with different cancers, including BRCA, THCA, LIHC, SKCM, LGG, KIRP, READ, ACC, KIRC, and UVM.